RecruitingPhase 1NCT06622070

A Study of SPY002-072 in Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-072 in Healthy Participants

Sponsor

Spyre Therapeutics, Inc.

Enrollment

56 participants

Start Date

Nov 18, 2024

Study Type

INTERVENTIONAL

Conditions

Healthy

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria2

Healthy men and women
Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits

Exclusion Criteria5

Participation in more than one cohort
Evidence of clinically significant abnormality or disease
Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent
History of severe allergic reactions or hypersensitivity
Donation or loss of ≥ 1 unit of whole blood within 1 month prior to dosing

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSPY002-072

Experimental

OTHERPlacebo

Placebo

Locations(2)

Spyre Site 2

Cypress, California, United States

Spyre Site 1

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06622070

Related Trials

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location